BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China
· Delayed Price · Currency is CNY 40.92
+0.65 (1.61%)
Mar 6, 2026, 4:00 PM EST
SHA:688166 Revenue
In the year 2025, BrightGene Bio-Medical Technology had annual revenue of 1.22B CNY, down -4.59%. BrightGene Bio-Medical Technology had revenue of 349.39M in the quarter ending December 31, 2025, with 14.28% growth.
Revenue
1.22B
Revenue Growth
-4.59%
P/S Ratio
13.91
Revenue / Employee
1.06M
Employees
1,162
Market Cap
17.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.22B | -58.91M | -4.59% |
| Dec 31, 2024 | 1.28B | 103.03M | 8.74% |
| Dec 31, 2023 | 1.18B | 162.19M | 15.94% |
| Dec 31, 2022 | 1.02B | -35.08M | -3.33% |
| Dec 31, 2021 | 1.05B | 267.03M | 34.00% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinocelltech Group | 1.56B |
| Jinyu Bio-technology | 1.33B |
| Anhui Anke Biotechnology (Group) | 2.58B |
| Inner Mongolia Furui Medical Science | 1.47B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Vcanbio Cell & Gene Engineering Corp., | 1.47B |
| Suzhou Zelgen Biopharmaceuticals | 812.73M |
| Mabwell (Shanghai) Bioscience | 662.52M |